# Appendix 3Z

Rule 3.19A.3

# **Final Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	ARGENT BIOPHARMA LIMITED
ABN	30 116 9800 269

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Layton Mills
Date of last notice	28 March 2024
Date that director ceased to be director	5 March 2025

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

## Number & class of securities

Nil

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
DJS Family Trust <layton atf="" djs<br="" mills="">Family Trust&gt;</layton>	120,000 Unlisted Options exercisable at A\$0.42 on or before 28 March 2027

#### Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A

<sup>+</sup> See chapter 19 for defined terms.

Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

<sup>+</sup> See chapter 19 for defined terms.